Cost-effectiveness of Varenicline versus existing alternatives for smoking cessation using the BENESCO model in the costarican adult population

Versión traducida del artículo "Costo-efectividad del uso de la Vareniclina versus las alternativas existentes para la cesación del fumado usando el modelo BENESCO en la población adulta costarricense" DOI: https://doi.org/10.51481/amc.v52i4.677

Autores/as

  • Manfred Lutz Pfizer
  • Eric Heibron Pfizer

DOI:

https://doi.org/10.51481/amc.v52i4.746

Palabras clave:

Pharmacoeconomics, cost-effectiveness, Varenicline, BENESCO simulation model, smoking cessation, life prevalence

Resumen

Aim: Tobacco use is one of the most serious health problems worldwide and it´s a preventable addiction; this is why the availability of treatments to quit smoking represents a great benefit to each individual's health as to institutional systems. Given the use of new treatments, particularly Varenicline, the available choices in Costa Rica must be comparatively evaluated because it is not clear which therapeutic option is the best and which generates the best cost-effectiveness ratio. The aim of this study was to model the cost-effectiveness of the therapeutic options for smoking cessation available in Costa Rica using the BENESCO model.

Methods: The BENESCO model was used to simulate the morbidity and mortality of the smoking population of Costa Rica, for both genders, between 18 and 99 years old. In this model, each smoker makes only one attempt to quit smoking at the beginning of the simulation. The strategies compared were: Varenicline, Bupropion, Nicotine replacement therapy, self determination (without intervention) and motivational group-speeches. The smoking-related diseases taken into account were: acute myocardial infarction, chronic obstructive pulmonary disease, stroke and lung cancer. The prevalence, incidence and mortality were obtained and calculated from the Costarican Social Security´s (CCSS) data base and the Institute of Alcoholism and Pharmacodependence of Costa Rica (IAFA). The costs of the diseases were calculated and updated to September, 2008.Deterministic, probabilistic and sensitivity analyses were carried out.

Results: Of all the strategies for smoking cessation, Varenicline was the therapeutic alternative with the less mortality and morbidity in the studied years. Regarding costs, Varenicline was also the less expensive option after the fifth year. After 2 years, motivational speeches were ¢3.443.167 cheaper than Varenicline. The intervention with the largest number of quality-adjusted life years and gained life years was Varenicline. Varenicline was the most effective option in the cost-incremental analysis, this means, it was clinically the most.

Conclusion: The results obtained suggest that Varenicline is the best cost-effective intervention for smoking cessation in comparison with Bupropion, NRT, self determination and motivational speeches. It was proven that Varenicline represents important economic savings for health systems and health institutes using it, since it reduces morbidity and the costs related to tobacco-associated diseases.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

WHO Report on the Global Tobacco Epidemia. The MPOWER Package. En: http://www.who.int/tobacco/mpower/en/. Consultado el 18 de julio del 2008.

US Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.

Bejarano J. Consumo de Drogas en Costa Rica. Resultados de la Encuesta Nacional del 2000-2001. Instituto sobre Alcoholismo y Farmacodependencia, 2003.

Araya R, Guzman M, Padilla S. Mortalidad por infarto agudo de miocardio: distribución geográfica y lugar de ocurrencia. Costa Rica, 1970 - 2002. Rev costarric cardiol 2003; 3: 25-29.

Departamento de información estadística de los servicios de salud. Cambios en morbilidad y mortalidad por edad y sexo Costa Rica: 1987, 1992, 1997 y 2002. Caja Costarricense del Seguro Social, 2003.

Unidad de Estadística del Ministerio de Salud de Costa Rica. Indicadores de salud. Ministerio de Salud, 2004. En: http://www. ministeriodesalud.go.cr/indicadoressalud/ib04retiro.pdf Consultado el 25 de octubre del 2008

Departamento de Estadística de Salud. Variaciones cronológicas y geográficas del cáncer de pulmón, piel y otros de menor frecuencia, 1956-57 a 2002-2003. Caja Costarricense del Seguro Social, 2005

Valencia A, Heredia I, Ventura C. Costo-efectividad del uso de Vareniclina como alternativa para dejar de fumar en la población derechohabiente al IMSS. Instituto Nacional de Salud Pública, 2007.

Población total proyectada por sexo, según años calendarios. Hipótesis recomendada 2000-2050. INEC. Costa Rica. En http://www.inec.go .cr/01EstadPoblacion/04estimacionesYproyec/proyecciones/cuadros/ cuadros/C1.%20Población%20total%20proyectada%20por%20 sexo,%20según%20años%20calendario.%20%20Hipótesis%20 recomendada.%20%202000-2050/Cuadro%201.proy.xls. Consultado el 25 de octubre del 2008.

Bejarano J, Fonseca S, Sánchez G. Consumo de drogas en Costa Rica. Resultados de la encuesta nacional 2006. San José, C.R.: Instituto sobre Alcoholismo y Farmacodependencia. En http://www.iafa.go.cr/

Estadisticas%20y%20Estudios/Estudios%20y%20encuestas/

Consultado el 10 de enero del 2009

Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26:497-511.

Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy. Cost-utility results for Sweden 2003. Respir Med 2008; 102:699-710.

Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Costeffectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24:51-61.

Champix BENESCO Long-term Cost Effectiveness Model. Technical Report. Commercial in confidence. January 2007.

Reus VI, Obach RS, Coe JW, Faessel H, Rollema H, Watsky E, Reeves K. Varenicline: new treatment with efficacy in smoking cessation. Drugs Today 2007; 43: 65-75.

Schnoll, Robert A, Lerman Caryn. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion Emerging Drugs. 2006;11:429-44.

Departamento de Estadística de la CCSS. Costo por consulta, 2007. CCSS, Costa Rica. En http://www.ccss.sa.cr/html/transparencia/ estadisticas/actuarial/estadist/anuarios/anuar07AV/ce5207.xls. Consultado el 25 de octubre del 2008.

I. McDowell K. Mothersill W. Rosser R. Hartman: A Randomized Trial of Three Approaches to Smoking Cessation. Can Fam Physician 1985; 31:845-851.

Banco Central de Costa Rica. Tipo de cambio de venta del dólar de los Estados Unidos de América. En http://www.bccr.fi.cr/flat/bccr_ flat.htm . Consultado el 25 de octubre del 2008.

Descargas

Publicado

2010-09-20

Cómo citar

Lutz, M., & Heibron, E. (2010). Cost-effectiveness of Varenicline versus existing alternatives for smoking cessation using the BENESCO model in the costarican adult population: Versión traducida del artículo "Costo-efectividad del uso de la Vareniclina versus las alternativas existentes para la cesación del fumado usando el modelo BENESCO en la población adulta costarricense" DOI: https://doi.org/10.51481/amc.v52i4.677. Acta Médica Costarricense, 52(4), 211–220. https://doi.org/10.51481/amc.v52i4.746